NewVac is engaged in the research and development of personalized and combination approaches to cancer therapy. Under a license agreement with Janssen, a subsidiary of the Johnson & Johnson Group, Newvac has obtained the right to develop, research and commercialize quisinostat, which is an inhibitor of histone deacetylases (HDACs). Quisinostat has highly specific antitumor activity and relatively low toxicity, which makes it a promising drug for oncotherapy.